Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab for Recurrent PCNSL
NCT04070040Phase 2Recruiting
- Sponsor
- Beijing Sanbo Brain Hospital
- Start
- Feb 2020
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in primary central nervous system lymphoma (PCNSL), sponsored by Beijing Sanbo Brain Hospital. Started Feb 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04070040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070040.